Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.
Ventyx Biosciences has raised $27.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2024.
Ventyx Biosciences's investors include Cormorant Asset Management, Vivo Capital, Janus Henderson Investors, Wellington Management, Adage Capital Management.
Ventyx Biosciences is headquartered in San Diego, United States.
Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.
Ventyx Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ventyx Biosciences — Funding & Investors." VCBacked, September 23, 2024, https://www.vcbacked.co/company/ventyx-biosciences. Accessed July 19, 2026.
VCBacked. (2024). Ventyx Biosciences — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/ventyx-biosciences
{{cite web |title=Ventyx Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/ventyx-biosciences |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated